Altre lingue Enlivex Therapeutics Ltd.

Azioni

ENLV

IL0011319527

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
1,61 ^USD	-3,59%		+7,33%	-40,37%

16/04	Enlivex Therapeutics Ltd annuncia l'autorizzazione dell'Agenzia regolatoria danese per lo studio di Fase I/II, randomizzato e controllato, che valuta Allocetra nei pazienti con osteoartrite del ginocchio.	CI
12/04	ENLIVEX THERAPEUTICS LTD. : HC Wainwright è per il Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Enlivex Therapeutics : Report of Periodic or Interim Report	30/04
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events	29/04
Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	22/04
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	22/04
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	22/04
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	16/04
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	16/04
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	16/04
Sector Update: Health Care Stocks Softer Late Afternoon	11/04
Sector Update: Health Care	11/04
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis	11/04
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study	11/04
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis	11/04
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis	11/04
Enlivex Therapeutics : Notes to Consolidated Financial Statements - Form 6-K	29/03
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.	29/03
Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	07/02
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	07/02
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	07/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Enlivex Therapeutics Ltd.

Azioni

ENLV

IL0011319527

Altre lingue

Filtri